Yazarlar : Nishihori T, Perkins J, Mishra A

Yayın : Biol Blood Marrow Transplant.

Yayın Yılı : 2014

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/24534108

Konu : MDS

Literatür İçeriği : We prospectively evaluated the allogeneic hematopoietic cell transplantation (HCT) outcomes in high-risk myelodysplastic syndrome (MDS) patients who received pre-transplant 5-azacitidine. Twenty five patients evaluated for allogeneic HCT consult and considered medically eligible for a donor search were enrolled. Azacitidine was administered at 75 mg/m² for 5 to 7 days every 4 weeks until a suitable donor was found. A median of 3 (0-6) cycles of 5-azacitidine was administered. Pre-allogeneic HCT responses to 5-azacitidine based on the International Working Group criteria were 48% partial response, 33% stable disease, and 19% progressive disease. Four patients did not proceed to allogeneic HCT. Twenty one patients, a median age of 55 (25 -67) years, received allogeneic HCT following myeloablative pharmacokinetically targeted IV busulfan and fludarabine conditioning regimen. Donors were either HLA-matched related or unrelated except for one mismatch unrelated donor. With a median follow up of 30 months, 1-year relapse-free and overall survivals were 52% (95%CI, 30% - 71%) and 62% (95%CI, 38% - 79%), respectively. Pre-allogeneic HCT 5-azacitidine administration was well tolerated and provided reasonable disease control prior to allogeneic HCT. (Registered at ClinicalTrials.gov as NCT00660400).

Literatür Arşivi